{"nctId":"NCT00232739","briefTitle":"Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions","startDateStruct":{"date":"2003-09"},"conditions":["Coronary Artery Disease"],"count":100,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Device: CYPHER Sirolimus-eluting Coronary Stent"]}],"interventions":[{"name":"CYPHER Sirolimus-eluting Coronary Stent","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or non-pregnant female patients minimum 18 years of age\n2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B\\&C, I-II) OR patients with documented silent ischemia;\n3. Target lesion is 20mm in length (visual estimate);\n4. Target lesion stenosis is \\>50% and \\<100% (visual estimate);\n\nExclusion Criteria:\n\n1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \\>2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;\n2. Has unstable angina classified as Braunwald III B or C, or is having a peri infarction;\n3. Documented Left ventricular ejection fraction 25%;\n4. Impaired renal function (creatinine \\> 3.0 mg/dl) at the time of treatment;","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure","description":"In-lesion restenosis was defined as over 50 percent diameter stenosis either within the stented segment or within 5 mm proximal or distal to the stent edges at a qualifying follow-up angiogram.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Percentages of Participants Who Experienced Any Major Adverse Cardiac Events up to Each Scheduled Follow-up","description":"The percentages are cumulative up to each of the scheduled post-procedure follow-up: 30 days, 6, 9, and 12 months, and 2, 3, 4 and 5 years. Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced Any Angiographic In-stent Binary Restenosis up to 6 Months Post-procedure.","description":"In-stent restenosis was defined as greater than or equal 50 percent diameter stenosis within the stented segment at a qualifying follow-up angiogram.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Average In-stent and In-lesion Minimum Lesion Diameters (MLD) at 6 Months Post-procedure.","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.64","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Cumulative Percentages of Participants Who Experienced Any Target Lesion Revascularization (TLR) up to 6 and 9 Months Post-procedure.","description":"TLR was defined as any \"clinically-driven\" repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Percentages of Participants Who Experienced Any Target Vessel Revascularization (TVR) up to 6 and 9 Months Post-procedure.","description":"TVR was defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations were those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis being greater than or equal to 50 percent measured by QCA.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Percentages of Participants Who Experienced Any Target Vessel Failure (TVF) up to 6 and 9 Months Post-procedure","description":"TVF was defined as any Target vessel revascularization, Q wave or non-Q wave MI, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Lumen Volume (mm3) at Post-procedure","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.34","spread":"38.32"}]}]}]},{"type":"SECONDARY","title":"Average Stent Obstruction Volume at Post-procedure","description":"Stent obstruction Volume equals 100 \\* \\[1-(lumen volume/baseline stent volume)\\]; usually this is equal to zero at baseline, since the stent is freshly implanted and no obstruction is expected","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Average Lumen Volume (mm3) at 6 Months Post-procedure","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.25","spread":"25.61"}]}]}]},{"type":"SECONDARY","title":"Average Stent Obstruction Volume at 6 Months Post-procedure","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.05","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Lesion Success at Post-procedure","description":"Lesion success defined as the attainment of \\<50 percent residual stenosis (by QCA) using any percutaneous method","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Device Success at Post-procedure","description":"Device success was defined as achievement of a final residual diameter stenosis of less than 50 percent as measured by QCA, using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieved Procedure Success Before Hospital Discharge","description":"Procedure success defined as achievement of a final diameter stenosis of less than 50 percent (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":91},"commonTop":["Target Vessel Failure","Target Vessel Revascularization (All)","Myocardial Infarction (Q wave or Non-Q wave)","Target Lesion Revascularization","Target Vessel Revascularization not involving Target Lesion"]}}}